Qualitative limiting result in lung adenocarcinoma cell lines
Cell-based study · A549 and H1299 human lung adenocarcinoma cells [1]
In the representative western blots, the NOD-IN-1 lanes retained vimentin and acetylated vimentin-K104 signals relative to DMSO, without the marked reduction seen with MCC950. This is a qualitative comparison; no quantified NOD-IN-1 effect size or statistical null result is established.
| Endpoint | Reported result | Reference |
|---|---|---|
| Vimentin and vimentin-K104Ac protein signals, with GAPDH loading control | Qualitative western blot comparison No marked reduction apparent in the NOD-IN-1 lanes relative to DMSO in the displayed A549 and H1299 blots; no numerical effect or P value adopted. | [1] |
Literature-Reported Treatment Conditions
- Treatment concentration
- 10 µM
- Method
- Cell treatment followed by western blotting
- Vehicle
- DMSO control
- Co-treatment
- NOD-IN-1 tested separately from MCC950, CY-09 and Nodinitib-1; no combination efficacy claim.
- Reported limits
- Duration labels are not reliably legible in the retained small Figure 7 image; no duration claim is adopted. A numerical NOD-IN-1-specific effect and its statistical significance are not established by the reviewed panel.
Methods and source locations
Compound reported in the paper: NOD-IN-1; Compound label in the paper: NOD-IN-1, separate inhibitor comparison arm
A model-specific qualitative limiting observation, not proof of NOD1/NOD2 inactivity or NLRP11 target engagement.
Results 2.7; Figure 7B–C and caption; Experimental Section: Plasmids and Reagents, Cell Lines and Culture, Western Blot Analysis
Vimentin and vimentin-K104Ac protein signals, with GAPDH loading control: Western blot; Figure 7B (A549) and 7C (H1299). MCC950, CY-09 and Nodinitib-1 are separate comparison treatments. — Results 2.7; Figure 7B–C and caption; Experimental Section: Plasmids and Reagents, Cell Lines and Culture, Western Blot Analysis